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ABSTRACT
Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from multiple sclerosis
(MS) that is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). Prior
NMO diagnostic criteria required optic nerve and spinal cord involvement but more restricted
or more extensive CNS involvement may occur. The International Panel for NMO Diagnosis (IPND)
was convened to develop revised diagnostic criteria using systematic literature reviews and elec-
tronic surveys to facilitate consensus. The new nomenclature defines the unifying term NMO
spectrum disorders (NMOSD), which is stratified further by serologic testing (NMOSD with or
without AQP4-IgG). The core clinical characteristics required for patients with NMOSD with
AQP4-IgG include clinical syndromes or MRI findings related to optic nerve, spinal cord, area
postrema, other brainstem, diencephalic, or cerebral presentations. More stringent clinical crite-
ria, with additional neuroimaging findings, are required for diagnosis of NMOSD without AQP4-
IgG or when serologic testing is unavailable. The IPND also proposed validation strategies and
achieved consensus on pediatric NMOSD diagnosis and the concepts of monophasic NMOSD
and opticospinal MS. Neurology® 2015;85:177–189
GLOSSARY
ADEM 5 acute disseminated encephalomyelitis; AQP4 5 aquaporin-4; IgG 5 immunoglobulin G; IPND 5 International Panel
for NMO Diagnosis; LETM 5 longitudinally extensive transverse myelitis lesions; MOG 5 myelin oligodendrocyte glycopro-
tein; MS 5 multiple sclerosis; NMO 5 neuromyelitis optica; NMOSD 5 neuromyelitis optica spectrum disorders; SLE 5
systemic lupus erythematosus; SS 5 Sjögren syndrome.
Neuromyelitis optica (NMO) is an inflammatory CNS disorder distinct from multiple sclerosis
(MS).1,2 It became known as Devic disease following a seminal 1894 report.3,e1,e2 Traditionally,
NMO was considered a monophasic disorder consisting of simultaneous bilateral optic neuritis
and transverse myelitis but relapsing cases were described in the 20th century.3 MRI revealed
normal brain scans and$3 vertebral segment longitudinally extensive transverse myelitis lesions
(LETM) in NMO.4,e3 The nosology of NMO, especially whether it represented a topograph-
ically restricted form of MS, remained controversial.
A major advance was the discovery that most patients with NMO have detectable serum anti-
bodies that target the water channel aquaporin-4 (AQP4–immunoglobulin G [IgG]),5,6 are
highly specific for clinically diagnosed NMO, and have pathogenic potential.7,e4–e6 In 2006,
AQP4-IgG serology was incorporated into revised NMO diagnostic criteria that relaxed clinical
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requirements by permitting unilateral optic
neuritis or asymptomatic brain MRI lesions
but retained the requirement for both myelitis
and optic neuritis.2 The 2006 criteria were
validated in several different ethnic and racial
cohorts worldwide and became the standard
for clinical and research purposes.8–10,e5,e7–e15
The specificity of AQP4-IgG facilitated ob-
servations that further broadened the clinical
and neuroimaging spectrum of NMO. In
2007, the term NMO spectrum disorders
(NMOSD) was introduced to include AQP4-
IgG-seropositive patients with limited or inau-
gural forms of NMO (e.g., first-attack LETM
or recurrent or bilateral optic neuritis) who
were at high risk for future attacks.1 The
NMOSD term also encompassed the cerebral,
diencephalic, and brainstem lesions that occur
in a minority of patients with otherwise typical
NMO. It also included AQP4-IgG-seropositive
patients with coexisting autoimmune disorders
(e.g., systemic lupus erythematosus [SLE] or
Sjögren syndrome [SS]). Finally, NMOSD
potentially included patients diagnosed with
opticospinal MS, an MS phenotype prominent
in Asia and distinguished from Western MS.11
Further advances have rendered the 2006 cri-
teria inadequate for contemporary practice and
research. Improvement in AQP4-IgG sensitivity
has allowed for refinement of the list of non-
opticospinal disease characteristics.12–14,e16–e18
Moreover, loss of AQP4 immunoreactivity
and astrocyte pathology in brain and spinal
cord NMO lesions distinguish them from
MS lesions.e19–e23 Together, these data sug-
gest that non-opticospinal clinical and MRI
characteristics should be incorporated into
the diagnostic criteria. The term NMOSD
has also been used variably in the literature
and needs clarification.3 Other outstanding
issues include whether there are distinctive
features of pediatric NMO, the current value
of the term opticospinal MS, and whether
monophasic NMO can be defined. Finally,
treatment strategies for attack prevention in
NMO and MS differ. Some MS immuno-
therapies appear to aggravate NMO, indicat-
ing an imperative for early, accurate
diagnosis.15–18,e24–e26 The International Panel
for NMO Diagnosis (IPND) was convened
and charged with revising NMO diagnostic
criteria for clinical decision-making and to
address the ancillary issues outlined above.
This report represents the Panel’s consensus
recommendations.
METHODS The IPND consisted of 18 members from 9 coun-
tries and was led by 2 co-chairs (D.M.W., B.G.W.). It convened
7 times between October 2011 and November 2013. Panel
members participated in 6 Working Groups: Clinical
Presentation, Neuroimaging, Laboratory Studies/Serology,
Pediatrics, Systemic Autoimmunity, and Opticospinal MS.
Initial consensus was reached on 2 points. First, NMOwould
be subsumed into the single descriptive term NMOSD because
the clinical behavior, immunopathogenesis, and treatment of pa-
tients who have NMOSD are not demonstrably different than for
those with NMO and patients with incomplete forms of NMO
frequently later fulfill NMO criteria.1,14,19,20,e27 The entrenched
and historically significant phrase NMO would be retained by
using NMOSD because, although the criteria would be broad-
ened to include patients with neither optic neuritis or myelitis,21
those syndromes eventually occur in almost all patients. Second,
revised criteria would define a clinical diagnosis by integrating
clinical, serologic, and neuroimaging data; diagnosis would not be
based solely on detection of AQP4-IgG. Moreover, the Panel
concluded that criteria must define NMOSD in instances where
AQP4-IgG serologic testing is negative or unavailable, especially
because of the treatment implications.
The IPND established several goals, chief of which was devel-
oping revised consensus NMOSD criteria using the best available
evidence. The Clinical Presentation Working Group conducted
the primary task of establishing the spectrum and validity of clin-
ical syndromes described in clinically diagnosed NMO or in asso-
ciation with AQP4-IgG; these data were used to establish new
core clinical criteria. The other Working Groups each addressed
a roster of focused questions that would contribute to final diag-
nostic criteria.
Each Working Group conducted a systematic literature
review, with expert librarian assistance, to address its assignments.
Medical subject heading terms were used when possible and
MEDLINE, EMBASE, and other databases were searched from
1946–January 2012 with quarterly updates through January
15, 2014 (see table e-1 on the Neurology® Web site at
Neurology.org for search strategies and results). Two individuals
independently reviewed abstracts for relevance; discordant ratings
were resolved by consensus. Relevant full-text articles were inde-
pendently rated to identify those used for data extraction. Pub-
lications describing sensitivity and specificity of AQP4-IgG were
included if they compared groups diagnosed with clinical NMO
and MS.
The Clinical Presentation and Neuroimaging Working
Groups compiled a list of clinical syndromes and MRI character-
istics reported by more than one publication to be associated with
NMOSD or AQP4-IgG. Panel members rated the specificity of
these characteristics for NMOSD diagnosis using 2 electronic sur-
veys. Two additional surveys presented adult case vignettes that
contained information on clinical symptoms and signs (1–3 dis-
crete clinical events) with brain MRI, AQP4-IgG serostatus, and
other potential supportive criteria (optic nerve or spinal cord MRI
findings) or laboratory results (e.g., CSF data, visual evoked po-
tentials). Panel members assigned a diagnosis for each vignette:
definite NMOSD, indeterminate (requiring further data or
follow-up for confident diagnosis), or other (e.g., MS). A roster
of potential supportive clinical, MRI, and laboratory criteria was
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separately ranked for their influence on confidence in NMOSD
diagnosis. Characteristics or scenarios endorsed by a two-thirds
Panel majority as contributing to a confident clinical diagnosis of
NMOSD were used to develop separate requirements for AQP4-
IgG seropositive and seronegative patients. Recommendations
from individual Working Groups regarding pediatric NMOSD,
opticospinal MS, systemic autoimmunity, and monophasic dis-
ease were summarized. All IPND members endorsed the final
criteria.
RESULTS Consensus diagnostic criteria. Nomenclature.
The Panel reaffirmed the decision to unify the terms
NMO andNMOSD. Given the greater degree of diag-
nostic uncertainty and potential heterogeneity of sero-
negative NMOSD, criteria were developed for both
NMOSD with AQP4-IgG and NMOSD without
AQP4-IgG. An additional category of NMOSD with
unknown AQP4-IgG status may be used for patients
in whom serologic testing is unavailable. The nomen-
clature allows for future modifications based on poten-
tial discovery and validation of other biomarkers in
AQP4-IgG-seronegative patients who have otherwise
typical NMOSD clinical syndromes.
Clinical presentation. Consensus diagnostic criteria
for NMOSD are presented in table 1. Table e-2 contains
a glossary of terms to guide interpretation of individual
components of the criteria. The criteria allow NMOSD
diagnosis with occurrence of at least 1 of 6 core clinical
characteristics and detection of AQP4-IgG. The core
clinical characteristics each implicate 1 of 6 CNS regions:
optic nerve,19,e28–e31 spinal cord,20,e27,e32–e34 area postrema
of the dorsal medulla,22,23,e35 brainstem,24,e35–e38 dien-
cephalon,25,26,e39–e44 or cerebrum.27,28,e45–e48 Certain clini-
cal presentations are particularly suggestive of NMOSD:
optic neuritis that is simultaneously bilateral, involves the
optic chiasm, causes an altitudinal visual field defect, or
causes severe residual visual loss (acuity 20/200 or
worse)4,e49–e51; a complete (rather than partial) spinal
cord syndrome, especially with paroxysmal tonic
spasms4,29,e52; and an area postrema clinical syndrome
(16%–43% incidence) consisting of intractable hic-
cups or nausea and vomiting.22,23,e35 Clinical judgment
remains necessary because no characteristic is path-
ognomonic. For example, altitudinal visual field
defects may result from ischemic optic neuropathy
and bilateral simultaneous optic neuritis may occur
in MS.e53
Diagnostic requirements are more stringent for
patients in whom AQP4-IgG is not detected or for
whom testing is unavailable. Such individuals must
experience 2 or more different core clinical character-
istics (i.e., dissemination in space, affecting different
neuroanatomic regions) and other supportive MRI
characteristics meant to enhance diagnostic specificity
must also be present. At least one of the clinical events
must be one of the 3 most common clinical character-
istics of NMOSD: optic neuritis, transverse myelitis
(additional requirement: LETM MRI lesion), or an
area postrema clinical syndrome (additional require-
ment: associated medullary MRI lesion).22,23,30,e35
The 2 required core characteristics may occur with
a single clinical attack (e.g., classic Devic syndrome
with simultaneous optic neuritis and acute myelitis
with LETM) or multiple attacks.
The Panel reached several additional conclusions.
First, at least 1 discrete clinical attack of CNS symp-
toms must occur to establish NMOSD diagnosis.
Although asymptomatic AQP4-IgG seropositive sta-
tus may exist for years before clinical NMOSD pre-
sentation,e54 the natural history of asymptomatic
seropositivity is poorly understood. Second,
NMOSD diagnosis is not warranted in asymptomatic
patients with NMOSD-compatible MRI lesions
because the expected clinical course in such individuals
is unknown. Third, no clinical characteristic is path-
ognomonic of NMOSD. Accordingly, a single clinical
manifestation is not diagnostic when AQP4-IgG is not
detected. Finally, no single characteristic is exclusion-
ary but some are considered red flags (table 2) that
signal the possibility of alternative diagnoses.e55–e63
The main clinical red flags concern the temporal course
of the syndrome rather than the actual manifestations.
Most notably, a gradually progressive course of neuro-
logic worsening over months to years is very uncom-
mon (1%–2%) in NMOSD.31 However, after
Table 1 NMOSD diagnostic criteria for adult patients
Diagnostic criteria for NMOSD with AQP4-IgG
1. At least 1 core clinical characteristic
2. Positive test for AQP4-IgG using best available detection method (cell-based assay strongly
recommended)
3. Exclusion of alternative diagnosesa
Diagnostic criteria for NMOSD without AQP4-IgG or NMOSD with unknown AQP4-IgG status
1. At least 2 core clinical characteristics occurring as a result of one or more clinical attacks
and meeting all of the following requirements:
a. At least 1 core clinical characteristic must be optic neuritis, acute myelitis with LETM, or
area postrema syndrome
b. Dissemination in space (2 or more different core clinical characteristics)
c. Fulfillment of additional MRI requirements, as applicable
2. Negative tests for AQP4-IgG using best available detection method, or testing unavailable
3. Exclusion of alternative diagnosesa
Core clinical characteristics
1. Optic neuritis
2. Acute myelitis
3. Area postrema syndrome: episode of otherwise unexplained hiccups or nausea and vomiting
4. Acute brainstem syndrome
5. Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical
diencephalic MRI lesions (figure 3)
6. Symptomatic cerebral syndrome with NMOSD-typical brain lesions (figure 3)
Additional MRI requirements for NMOSD without AQP4-IgG and NMOSD with unknown
AQP4-IgG status
1. Acute optic neuritis: requires brain MRI showing (a) normal findings or only nonspecific white
matter lesions, OR (b) optic nerve MRI with T2-hyperintense lesion or T1-weighted gadolinium-
enhancing lesion extending over .1/2 optic nerve length or involving optic chiasm (figure 1)
2. Acute myelitis: requires associated intramedullary MRI lesion extending over $3 contiguous
segments (LETM) OR $3 contiguous segments of focal spinal cord atrophy in patients with
history compatible with acute myelitis (figure 1)
3. Area postrema syndrome: requires associated dorsal medulla/area postrema lesions (figure 2)
4. Acute brainstem syndrome: requires associated periependymal brainstem lesions (figure 2)
Abbreviations: AQP4 5 aquaporin-4; IgG 5 immunoglobulin G; LETM 5 longitudinally exten-
sive transverse myelitis lesions; NMOSD 5 neuromyelitis optica spectrum disorders.
a See table 2 and text discussion on serologic considerations for recommendations regard-
ing interpretation of clinical and serologic testing.
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thorough investigation for potential competing disor-
ders, the weight of evidence may justify NMOSD
diagnosis despite presence of 1 or more red flags.
The presence of systemic autoimmune diseases and
certain CSF data and pathologic findings (see below)
may also influence NMOSD likelihood. Regardless
of AQP4-IgG serologic status, NMOSD should be
diagnosed when criteria are fulfilled and alternative
diagnoses for the clinical syndrome have been
excluded.
Neuroimaging and neurophysiologic testing. MRI lesion
patterns are a major arbiter of CNS demyelinating
disease differential diagnosis. Several brain, optic
nerve, and spinal cord patterns are characteristic or
highly suggestive of NMOSD (table 3; figures 1–3).
Detection of a LETM spinal cord lesion (figure 1)
associated with acute myelitis is the most specific
neuroimaging characteristic of NMOSD and is very
uncommon in adult MS.2 Such lesions typically
involve the central gray matter and may be associated
with cord swelling, central hypointensity on T1-
weighted sequences, and enhancement following
IV gadolinium administration; extension of a
cervical lesion into the brainstem is characteris-
tic.4,32,33,e35,e64–e67 In contrast, MS cord lesions are
usually about 1 vertebral segment long or less, occupy
peripheral white matter tracts such as the dorsal col-
umns, and may be asymptomatic (see table 3 for
neuroimaging red flags relevant to MS and other dis-
eases).34–36,e68–e70 Although the LETM pattern is char-
acteristic of NMOSD, 7%–14% of initial and 8% of
subsequent myelitis attacks in AQP4-IgG-seroposi-
tive patients do not meet the LETM definition.32,37
Therefore, NMOSD must be considered in the dif-
ferential diagnosis in patients presenting with short
myelitis lesions. The timing of an individual MRI
scan must be correlated with clinical status. Occasion-
ally, lesions of less than 3 segments are detected in
NMOSD because the MRI was performed early in
the evolution of acute myelitis or in clinical remission,
during which a LETM lesion may fragment into dis-
continuous lesions.37,e71 Some patients with progress-
ive MS have coalescent cord lesions that can
superficially suggest a LETM patterne72; both axial
and sagittal plane images should be used to judge
lesion extent. A LETM MRI pattern may also occur
in patients with infectious, granulomatous, neoplas-
tic, and paraneoplastic diseases, acute disseminated
encephalomyelitis (ADEM), spinal cord infarction,
and dural arteriovenous fistula.e63
During optic neuritis attacks, increased signal
within the optic nerve may be detected with fat-
suppressed T2-weighted orbital MRI sequences,
typically with gadolinium enhancement seen on T1-
weighted sequences (figure 1). Bilateral optic nerve
involvement, posterior nerve predominance (especially
with extension into the optic chiasm), or extensive
lesions of the optic nerve (more than half of its length)
are all suggestive of NMOSD (table 3).e51,e73,e74
According to the 2006 diagnostic scheme, a nor-
mal brain MRI or detection of only nonspecific white
matter lesions was a key supportive criterion.2 Sixty
percent of patients with NMOSD accumulate asymp-
tomatic white matter lesions on longitudinal study
and as many as 16% fulfill Barkhof MS MRI crite-
ria.33,38,39,e75–e76 Detection of brain MRI white matter
lesions compatible with MS does not exclude the
diagnosis of NMOSD but is considered a red flag,
indicating that additional evidence may be required
to confidently distinguish NMOSD fromMS in indi-
vidual cases.33,38,e64,e76,e77 Analysis of qualitative fea-
tures of lesions assists in distinguishing NMOSD
Table 2 Red flags: Findings atypical for NMOSD
Red flags (clinical/laboratory)
1. Clinical features and laboratory findings
Progressive overall clinical course (neurologic deterioration unrelated to attacks; consider MS)
Atypical time to attack nadir: less than 4 hours (consider cord ischemia/infarction); continual
worsening for more than 4 weeks from attack onset (consider sarcoidosis or neoplasm)
Partial transverse myelitis, especially when not associated with LETMMRI lesion (consider MS)
Presence of CSF oligoclonal bands (oligoclonal bands occur in ,20% of cases of NMO vs
.80% of MS)
2. Comorbidities associated with neurologic syndromes that mimic NMOSD
Sarcoidosis, established or suggestive clinical, radiologic, or laboratory findings thereof (e.g.,
mediastinal adenopathy, fever and night sweats, elevated serum angiotensin converting
enzyme or interleukin-2 receptor levels)
Cancer, established or with suggestive clinical, radiologic, or laboratory findings thereof;
consider lymphoma or paraneoplastic disease (e.g., collapsin response mediator protein-5
associated optic neuropathy and myelopathy or anti-Ma-associated diencephalic syndrome)
Chronic infection, established or with suggestive clinical, radiologic, or laboratory findings
thereof (e.g., HIV, syphilis)
Red flags (conventional neuroimaging)
1. Brain
a. Imaging features (T2-weighted MRI) suggestive of MS (MS-typical)
Lesions with orientation perpendicular to a lateral ventricular surface (Dawson fingers)
Lesions adjacent to lateral ventricle in the inferior temporal lobe
Juxtacortical lesions involving subcortical U-fibers
Cortical lesions
b. Imaging characteristics suggestive of diseases other than MS and NMOSD
Lesions with persistent (.3 mo) gadolinium enhancement
2. Spinal cord
Characteristics more suggestive of MS than NMOSD
Lesions ,3 complete vertebral segments on sagittal T2-weighted sequences
Lesions located predominantly (.70%) in the peripheral cord on axial T2-weighted
sequences
Diffuse, indistinct signal change on T2-weighted sequences (as sometimes seen with
longstanding or progressive MS)
Abbreviations: LETM 5 longitudinally extensive transverse myelitis lesions; MS 5 multiple
sclerosis; NMO 5 neuromyelitis optica; NMOSD 5 neuromyelitis optica spectrum disorders.
These are some common or key findings that should prompt thorough investigation for
competing differential diagnoses before making a diagnosis of NMOSD.
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from MS. First, at least 7% of patients have
NMOSD-typical patterns that, although not pathog-
nomonic for NMOSD, are considered exceptional for
MS (table 3),39 including lesions of the dorsal
medulla/area postrema (figure 2)22,33,40,e36,e73,e78
and periependymal regions in the brainstem
(figure 2)33,40,e36,e73 and diencephalic struc-
tures,39,40,e79 or cerebral hemispherese80 (figure 3),
or long lesions spanning much of the length of the
corpus callosum39,41 or corticospinal tracts
(figure 3).33,34 Large, confluent, or tumefactive
cerebral lesions may suggest NMOSD but in isola-
tion may not be discernable from atypical MS
lesions, especially in AQP4-IgG-seronegative pa-
tients.27,33,39,42,e46,e812e83 Second, some MRI lesion
patterns considered typical of MS are rarely seen in
NMOSD, including perpendicular orientation of
periventricular lesions (Dawson fingers), periven-
tricular lesions located in the inferior temporal lobe,
and cortical lesions.33,38,43,e64 Recent 7T MRI stud-
ies revealed differences between NMOSD and MS
specifically regarding cortical lesions (frequent in
MS but absent in NMOSD) and white matter
lesions (MS plaques are periventricular and tra-
versed by a central venule whereas NMOSD lesions
are subcortical and lack a central venule).e84,e85
However, this technology is not widely available
and further validation is needed.
The Panel considered evidence for use of other
imaging modalities, such as nonconventional MRI
techniques and optical coherence tomography, and
neurophysiologic tests such as visual evoked poten-
tials. None of these modalities were included in the
revised diagnostic criteria because of concerns regard-
ing lack of evidence, specificity, or reliability.
Considerations for AQP4-IgG serologic and other
laboratory testing. Technological advances in AQP4-
IgG assays have improved diagnostic sensitivity
without compromising specificity.44 The Panel
recommended testing with cell-based serum assays
(microscopy or flow cytometry-based detection)
whenever possible because they optimize autoantibody
detection (mean sensitivity 76.7% in a pooled analysis;
0.1% false-positive rate in a MS clinic cohort).12–14,44,45
However, cell-based assays are not yet widely available.
Indirect immunofluorescence assays and ELISAs
have lower sensitivity (mean sensitivity 63%–64% each)
and occasionally yield false-positive results (0.5%–1.3%
for ELISA), often at low titer.12–14,44,45,e86 The Panel
strongly recommended interpretative caution if such as-
says are used and when low-titer positive ELISA results
are detected in individuals who present with NMOSD
clinical symptoms less commonly associated with AQP4-
IgG (e.g., presentations other than recurrent optic neu-
ritis, myelitis with LETM, or area postrema syndrome)
or in situations where clinical evidence suggests a viable
alternate diagnosis. Confirmatory testing is recom-
mended, ideally using 1 or more different AQP4-
IgG assay techniques. Cell-based assay has the best
current sensitivity and specificity and samples may
need to be referred to a specialized laboratory.
Patients who fulfill NMOSD criteria but do not
have detectable AQP4-IgG despite use of the best
available assays, or for whom serologic testing is
unavailable, sometimes represent a diagnostic chal-
lenge.46 A greater proportion of patients with NMO
who have monophasic disease appear to be AQ-
P4-IgG-seronegative compared to those with estab-
lished relapsing disease.37 A minority of patients with
clinical characteristics of NMO, almost all AQP4-
IgG-seronegative, have been reported to have detect-
able serum myelin oligodendrocyte glycoprotein
Table 3 Neuroimaging characteristics of NMOSD
Spinal cord MRI, acute
LETM lesion associated with acute TM
Increased signal on sagittal T2-weighted (standard T2-weighted, proton density, or STIR
sequences) extending over 3 or more complete vertebral segments (figure 1, A and D)
Central cord predominance (more than 70% of the lesion residing within the central gray
matter) (figure 1, A–D)
Gadolinium enhancement of the lesion on T1-weighted sequences (no specific distribution or
pattern of enhancement is required) (figure 1, C, E, and F)
Other characteristic features that may be detected
Rostral extension of the lesion into the brainstem (figure 1, D and E)
Cord expansion/swelling
Decreased signal on T1-weighted sequences corresponding to region of increased
T2-weighted signal (figure 1F)
Spinal cord MRI, chronic
Longitudinally extensive cord atrophy (sharply demarcated atrophy extending over $3
complete, contiguous vertebral segments and caudal to a particular segment of the spinal
cord), with or without focal or diffuse T2 signal change involving the atrophic segment (figure 1,
G and H)
Optic nerve MRI
Unilateral or bilateral increased T2 signal or T1 gadolinium enhancement within optic nerve or
optic chiasm (figure 1, I–K); relatively long lesions (e.g., those extending more than half the
distance from orbit to chiasm) and those involving the posterior aspects of the optic nerves or
the chiasm are associated with NMO
Cerebral MRI: NMOSD-typical brain lesion patterns (increased signal on T2-weighted MRI
sequences unless otherwise noted)
Lesions involving the dorsal medulla (especially the area postrema), either small and localized,
often bilateral, or contiguous with an upper cervical spinal cord lesion (figure 2, A–E)
Periependymal surfaces of the fourth ventricle in the brainstem/cerebellum (figure 2, F–H)
Lesions involving the hypothalamus, thalamus, or periependymal surfaces of the third ventricle
(figure 3, A and B)
Large, confluent, unilateral, or bilateral subcortical or deepwhite matter lesions (figure 3, C and D)
Long (1/2 of the length of the corpus callosum or greater), diffuse, heterogeneous, or
edematous corpus callosum lesions (figure 3E)
Long corticospinal tract lesions, unilateral or bilateral, contiguously involving internal capsule
and cerebral peduncle (figure 3F)
Extensive periependymal brain lesions, often with gadolinium enhancement (figure 3, G–I)
Abbreviations: LETM 5 longitudinally extensive transverse myelitis lesions; NMOSD 5 neu-
romyelitis optica spectrum disorders; STIR 5 short tau inversion recovery.
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(MOG) antibodies and might have different charac-
teristics (younger age, less frequently female, and less
likely to relapse) from those with AQP4-IgG.47–49,e87
These findings might suggest that some AQP4-IgG-
seronegative patients with clinical and neuroimaging
features of NMOSD have a different underlying
pathogenesis46; the role of MOG or other antibodies
in disease pathogenesis remains undetermined.e88 The
IPND nomenclature is designed to allow incorpora-
tion of cases of NMOSD associated with other vali-
dated biomarkers (e.g., NMOSD with a specific
autoantibody).
Figure 1 Spinal cord and optic nerve MRI patterns in neuromyelitis optica spectrum disorder
Spinal cord imaging in the context of acute myelitis in neuromyelitis optica spectrum disorders (NMOSD) usually reveals a
longitudinally extensive transverse myelitis (LETM) lesion extending over 3 or more vertebral segments. Sagittal T2-
weighted MRI of the thoracic spinal cord (A) demonstrates a typical LETM lesion involving most of the thoracic spinal cord
(arrows). LETM lesions have a predilection for the central cord, as shown by axial T2-weighted (B; arrowhead) and T1-
weighted MRI with gadolinium (C; arrowhead). Cervical LETMmay extend into the medulla, a characteristic NMOSD pattern
demonstrated in D (arrows; sagittal T2-weighted MRI) and E (arrows; sagittal T1-weighted MRI with gadolinium). Acute
LETM lesions can be associated with intralesional hypointensity as shown by sagittal T1-weighted MRI (F; arrow); in this
example, a rim of gadolinium enhancement surrounds the hypointense region. Chronic sequelae of LETM may include lon-
gitudinally extensive segments of spinal cord atrophy as shown by T2-weightedMRI using sagittal (G; the 2 arrowheads indi-
cate the atrophic segment and the top arrow indicates the normal diameter of unaffected cervical spinal cord) and axial
planes (H; arrowhead shows an atrophic spinal cord). Fast spin echo fat-suppressed T2-weighted MRI in the axial (I) and cor-
onal (J) planes shows increased signal throughout most the length of the left optic nerve, especially its posterior portion
(arrows). Axial T1-weightedMRI with gadolinium shows enhancement of the optic chiasm (K; arrows). These images are from
2 different patients experiencing acute optic neuritis in the setting of NMOSD.
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Occasionally, patients without detectable serum
AQP4-IgG are later found to be seropositive. There
may be technical explanations in some cases but anti-
body levels also increase with clinical relapses and
decrease with immunosuppressive therapy in some
patients.50 Therefore, retesting should be considered
before B-cell or antibody-targeted therapies (plasma
exchange, immunosuppressive drugs) are instituted
and in seronegative patients who relapse.51 Cases of
clinical NMO in which AQP4-IgG was detected in
CSF, but not serum, have been reported but this
appears to be rare.52,e89–e91 Routine CSF testing of
AQP4-IgG-seronegative patients is not recommen-
ded but might be considered in selected seronegative
cases, especially those with additional confounding
serum autoantibodies that may lead to uninterpret-
able or false-positive assay results.
The Panel considered absence of CSF oligoclonal
bands as supportive evidence for NMOSD (although
they are sometimes transiently detectable at the time
of an attack) and presence of bands a red flag, but sen-
sitivity and specificity are modest.4,53 CSF pleocytosis
.50 leukocytes/mL (incidence approximately 35% in
NMOSD) or the presence of neutrophils or eosino-
phils (either .5/mL; incidence 44% and 10%,
respectively, in attack-associated samples) are partic-
ularly useful in distinguishing NMOSD from MS.4,53
CSF glial fibrillary acidic protein also shows promise
as a diagnostic and prognostic biomarker but is ele-
vated only for days to weeks following an attack.e92,e93
Pediatric NMOSD criteria. The Pediatric Working
Group members noted that most clinical, neuroimag-
ing, and laboratory characteristics of pediatric NMOSD
are similar to those of adult-onset disease. The female
preponderance may be of lower magnitude (;3:1
female:male ratio compared with up to 9:1 for
adults),54,e94 a greater proportion of children may have
monophasic disease,54,55,e95 and acute CSF abnormalities
in pediatric MS may mimic those ordinarily considered
suggestive of NMOSD.54–56 The Working Group
identified caveats to application of the adult NMOSD
criteria in children, noting especially that detection of a
LETMMRI lesion associated with acute myelitis may be
less specific for NMOSD. Approximately 15% of
children with MS may have LETM during relapse,
LETM can accompany monophasic ADEM, and
AQP4-IgG is rarely detected in children with
monophasic LETM.55 In children diagnosed with
ADEM according to international consensus criteria,
which require a polyfocal demyelinating clinical
presentation with encephalopathy,57 the presence of
AQP4-IgG favors a diagnosis of NMOSD, although
prospective validation studies are required to
determine risk of recurrent NMOSD events. In one
study of AQP4-IgG-seropositive children, 45%
Figure 2 Dorsal medulla, area postrema, and other brainstem lesions in
neuromyelitis optica spectrum disorder
Sagittal T2-weighted fluid-attenuated inversion recovery (FLAIR) MRI shows a lesion in the
dorsal medulla (A; arrow). Sagittal T2-weighted (B) and T1-weighted MRI with gadolinium (C)
each demonstrate an acute lesion (arrows) associated with area postrema clinical syndrome.
Axial T2-weighted FLAIR (D; arrows) and T1-weighted MRI with gadolinium (E; arrowheads)
show dorsal medulla involvement in a patient with acute area postrema clinical syndrome.
Axial T2-weighted FLAIR MRI shows periependymal lesions involving the pons (F; arrows)
and dorsal midbrain (G; arrow). Sagittal T2-weighted FLAIR MRI shows increased signal sur-
rounding the fourth ventricle (H; arrows).
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Figure 3 Diencephalic and cerebral lesions in neuromyelitis optica spectrum disorder
A variety of brain lesion patterns are associated with neuromyelitis optica spectrum disorder. Axial T2-weighted fluid-
attenuated inversion recovery (FLAIR) MRI from 2 patients demonstrates lesions involving the right thalamus (A; arrow)
and the hypothalamus (B; arrows). Axial T2-weighted FLAIR MRI shows an extensive subcortical white matter lesion
(C; arrow) that enhances after gadolinium administration on T1-weighted sequences (D; arrow). Chronic longitudinally
extensive and linear corpus callosum lesions are depicted on sagittal T2-weighted FLAIR MRI (E; arrows). Coronal
T2-weighted FLAIR MRI shows longitudinal involvement of the corticospinal tract extending to the cerebral peduncle
and pons (F; arrows). Acute periependymal cerebral lesions from one patient are depicted using sagittal (G; arrow) and
axial (H; arrows) T2-weighted FLAIR MRI and axial T1-weighted MRI with gadolinium (I; arrows).
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experienced recurrent cerebral manifestations including
encephalopathy.56 Aside from these caveats, the
currently proposed diagnostic criteria for NMOSD
are appropriate for pediatric patients. Longitudinal
observation of the clinical course for dissemination in
time and retesting the AQP4-IgG status of some
children, especially AQP4-IgG-seronegative individuals
presenting with an ADEM-like event that includes
optic neuritis and LETM, may be required to achieve
confident diagnosis.
Monophasic NMOSD. The occurrence of a second clin-
ical attack, which defines a relapsing disorder, was
often considered sufficient to revise the diagnosis to
MS in otherwise typical NMO cases. Approximately
5%–10% of contemporary cases are described as mon-
ophasic, although the optimal definition for monopha-
sic NMOSD remains elusive. It is unclear whether the
occurrence of bilateral optic neuritis and myelitis at
initial presentation are helpful or essential to distin-
guish such cases from relapsing NMOSD. Similarly,
the interval between index clinical events that is com-
patible with monophasic NMO has not been consis-
tently defined or adequately examined as a predictor of
future clinical course. Although early risk of relapse is
high in AQP4-IgG-seropositive cases (e.g., about 60%
within 1 year after LETM),20 cases have been
documented in whom more than a decade elapsed
between the index events and relapse.e34
Several studies show a pattern of apparently mon-
ophasic NMO being associated with a more equitable
sex distribution, relatively younger age at disease
onset, tendency to present with simultaneous myelitis
and bilateral optic neuritis (rather than unilateral
optic nerve involvement), lower frequency of other
autoimmune diseases, and lower prevalence of serum
AQP4-IgG compared to relapsing NMO.4,37,e96 A
fraction of these patients may have other serum anti-
bodies such as MOG-IgG.47
The Panel concluded that monophasic NMOSD
is a recognizable clinical entity but that criteria that
accurately predict long-term adherence to a mono-
phasic course cannot currently be defined. An interval
longer than 4 weeks between index attacks indicates
relapsing disease. The Panel also recommended that
at least 5 years (preferably longer) of relapse-free clin-
ical observation after the index events be required
before a monophasic course is assumed with any
degree of confidence. Patients who are AQP4-IgG-
seropositive should be assumed to be at risk for
relapse indefinitely and preventive treatment should
be considered, even in the setting of a prolonged clin-
ical remission.
Systemic autoimmunity associated with NMOSD. Based
on evidence from several observational studies, the
Panel concluded that clinical diagnoses of SLE, SS,
or myasthenia gravis may coexist with NMOSD clin-
ical syndromes in AQP4-IgG-seropositive patients
and, in fact, their presence strengthens confidence
about a NMOSD diagnosis.58,e97,e98 The underlying
cause of CNS symptoms and signs is more likely to be
co-associated NMOSD than a direct complication
(e.g., associated vasculitis) of SLE or SS. In a
patient suspected of having NMOSD, the presence
of clinical myasthenia gravis or detectable serum
acetylcholine receptor antibodies is considered
supportive of NMOSD diagnosis.e99–e101
Pathology. Pathologic findings in biopsy or autopsy tissue
obtained from patients with AQP4-IgG-seropositive
NMOSD demonstrate loss of AQP4 immunoreactivity
and evidence of perivascular complement activation in
actively demyelinating lesions.e20,e21 Additionally,
findings supportive of astrocytopathy such as truncated
astrocyte processes or cell loss may be detected by
immunostaining for glial fibrillary acidic protein.59,e20
These findings in active lesions distinguish AQP4-IgG-
positive NMOSD from MS; data from seronegative
individuals are not yet available.59 Necrosis and lesion
infiltration with neutrophils and eosinophils are
supportive characteristics,e102 but may not be present.
Spinal cord lesions may differ from supraspinal lesions
in this respect.e103 Serum AQP4-IgG testing usually
obviates the need for biopsy in severe myelitis and
leukoencephalopathy syndromes.e19,e104,e105 Aquaporin-4
immunostaining is not a routine procedure in CNS
biopsy processing and is available only in select centers.
The Panel does not recommend CNS biopsy but
recognizes that in atypical cases, expert pathologic
review of biopsy tissue of brain or spinal cord might
help establish NMOSD and exclude competing
diagnoses.60
Opticospinal MS. The term opticospinal MS was
introduced in Japan to refer to a pattern of MS that
is relatively more common in Asian countries.11,e106
It was defined by recurrent optic neuritis and myelitis
attacks with no brain involvement, although some
investigators allow occurrence of certain brainstem
syndromes.e107 The description of opticospinal MS
represented an important milestone because it recog-
nized that there was a relapsing illness distinct from
conventional MS that selectively targeted the optic
nerve and spinal cord at a time when relapses were
deemed to be incompatible with a diagnosis of NMO
in both Western countries and Japan.
Contemporary NMO criteria that include MRI
criteria for length of spinal cord lesions and detection
of AQP4-IgG are more specific than historical optico-
spinal MS criteria. Clinicians and investigators in
many Asian countries now use the term NMO rather
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than opticospinal MS in research and practice. When
similarly defined in Asia, NMO clinical syndromes
and brain MRI lesions are both analogous to those
encountered in Western countries.22,23,33,39,e108 The
Panel concluded that opticospinal MS is a historically
important but now superseded term, especially in
light of the need to distinguish NMO from MS to
guide treatment decisions.15–18,e24–e26
DISCUSSION The high specificity of AQP4-IgG has
been exploited to expand the clinical and
neuroimaging spectrum of NMO. The consensus
definition of NMOSD unifies traditional NMO and
modern NMOSD definitions. It allows for NMOSD
diagnosis in AQP4-IgG-seropositive patients with
involvement of almost any CNS region as well as in
those with restricted involvement of a single region
(e.g., recurrent transverse myelitis). For the first time,
criteria allow for NMOSD diagnosis in patients who
have not experienced clinical involvement of either
optic nerves or spinal cord. The Panel reached these
conclusions for the following reasons: (1) there are
no established biological differences between patients
diagnosed with NMO compared with NMOSD
(using 2006 and 2007 definitions, respectively)
in AQP4-IgG-seropositive patients; (2) limited
NMOSD syndromes affecting CNS regions other
than the optic nerve and spinal cord often herald
subsequent clinical attacks consistent with
conventional NMO in AQP4-IgG-positive patients;
and (3) current immunotherapeutic strategies are the
same for relapsing NMO and NMOSD, regardless
of AQP4-IgG serologic status. To enhance criteria
specificity, AQP4-IgG-seronegative patients must
have experienced at least one of the 3 most common
clinical characteristics of seropositive NMOSD,
namely optic neuritis, transverse myelitis with
LETM, or area postrema syndrome with associated
MRI lesions. These criteria are appropriate for adults
and, with minor caveats, children. Finally, the Panel
cautions against making a diagnosis of monophasic
NMOSD, especially in AQP4-IgG-seropositive
patients, and recommends abandonment of the term
opticospinal MS for cases that meet NMOSD criteria.
The IPND criteria are expected to facilitate earlier
and more accurate diagnosis by identifying individu-
als who would have been diagnosed with idiopathic
transverse myelitis, idiopathic optic neuritis, or atyp-
ical MS. This will be particularly true for AQP4-IgG-
seropositive patients experiencing their first CNS
attack (such patients will now meet NMOSD crite-
ria), leading to a specific treatment path with immu-
notherapy for attack prevention. The criteria should
also provide greater specificity for distinguishing both
AQP4-IgG-seropositive and AQP4-IgG-seronegative
NMOSD from MS. Early-stage diagnostic specificity
is critical because recent observational data suggest
that interferon-b, natalizumab, and fingolimod may
worsen NMO.15–18,e24–e26
The IPND criteria are expected to facilitate more
comprehensive and comparable epidemiologic studies
by supplying a uniform case definition and a glossary
of defined terms. For AQP4-IgG-seronegative cases
diagnosed using the new NMOSD scheme, detailed
clinical, neuroimaging, and laboratory descriptions
of patients will be necessary to better characterize this
heterogeneous population. This is particularly impor-
tant to identify the frequencies with which serocon-
version to AQP4-IgG positivity or detection of
other autoantibodies of interest occur and to identify
phenocopies later diagnosed as other conditions.
Many observations used to construct the IPND
criteria were derived from relatively small case series.
The Panel recommends several large-scale prospective
validation and assessment strategies. These include
but are not limited to studies that (1) systematically
apply the criteria to consecutive cases of NMOSD,
with and without AQP4-IgG, to determine whether
the diagnosis is confirmed or another alternative diag-
nosis emerges in follow-up; (2) validate the associa-
tion and potential immunopathogenesis of serum
MOG-IgG (and other future potential laboratory
and neuroimaging biomarkers) with clinically diag-
nosed NMOSD; (3) identify clinical settings in which
false-negative and false-positive AQP4-IgG results are
more likely; (4) validate different definitions predic-
tive of clinical course (monophasic vs relapsing) and
determine the distinguishing characteristics of these
subtypes; and (5) further examine the immunopa-
thology of NMOSD to determine whether there is
unrecognized heterogeneity to inform its classifica-
tion, especially of AQP4-IgG-seronegative cases.
These and other approaches to criteria validation will
allow future refinement of NMOSD diagnostic crite-
ria commensurate with the next era of scientific
advances.
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